|
|
Blood, 15 October 2008, Vol. 112, No. 8, pp. 3048-3051.
Prepublished online as a Blood First Edition Paper on September 5, 2008; DOI 10.1182/blood-2008-02-135715.
Previous Article | Table of Contents | Next Article 
CHEMOKINES, CYTOKINES, AND INTERLEUKINS
Brief Report
PI3Kgamma (PI3K ) is essential for efficient induction of CXCR3 on activated T cells
Joseph Barbi1,
Hannah E. Cummings1,
Bao Lu2,
Steve Oghumu1,
Thomas Rückle3,
Christian Rommel4,
William Lafuse5,
Caroline C. Whitacre5, and
Abhay R. Satoskar1
1 Department of Microbiology, The Ohio State University, Columbus;
2 Ina Sue Perlmutter Laboratory, Children's Hospital, Harvard Medical School, Boston, MA;
3 Merck Serono International SA, Geneva, Switzerland;
4 Intellikine, La Jolla, CA; and
5 Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus
The gamma isoform of PI3Kinase (PI3K ) controls leukocyte chemotaxis by participating in GPCR signaling, and by regulating cellular polarization. Here we show that PI3K is required for efficient induction of CXC chemokine receptor 3 (CXCR3) on T cells upon activation. T cells from PI3K –/– mice up-regulated CXCR3 less efficiently than wild-type controls both upon activation in vitro as well as during Leishmania mexicana infection. Inhibition of PI3Kinases using wortmannin and LY294002 or blockade of PI3K activity using a selective inhibitor or PI3K siRNA suppressed induction of CXCR3 on T cells following activation. Levels of CXCR3 and T-bet mRNA were significantly lower in PI3K inhibitor–treated T cells, indicating that PI3K may control CXCR3 expression in part through induction of T-bet. These results reveal a novel role for PI3K in the induction of CXCR3 on T cells and suggest that PI3K may regulate leukocyte chemotaxis by controlling the expression of chemokine receptors.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Younes
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
Hematology,
January 1, 2009;
2009(1):
507 - 519.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|